Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun;18(1):27-34.
doi: 10.17925/EE.2022.18.1.27. Epub 2022 May 20.

Review of Automated Insulin Delivery Systems for Type 1 Diabetes and Associated Time in Range Outcomes

Armaan Nallicheri  1 , Katherine M Mahoney  1 , Hanna A Gutow  1 , Natalie Bellini  2 , Diana Isaacs  3
Affiliations
Review

Review of Automated Insulin Delivery Systems for Type 1 Diabetes and Associated Time in Range Outcomes

Armaan Nallicheri et al. touchREV Endocrinol. 2022 Jun.

Abstract

Automated insulin delivery (AID) systems play an important role in the management of type 1 diabetes mellitus (T1DM). These systems include three components: a continuous glucose monitor (CGM), an insulin pump and an algorithm that adjusts the pump based on the CGM sensor glucose readings. They are not fully automated and still require the user to administer bolus insulin doses for food. Some AID systems have automatic correction boluses, while others only have automatic basal or background insulin adjustments. As CGM has become more accurate and the technology has evolved, AID systems have demonstrated improved glycaemic outcomes. The clinical evaluation of AID systems in randomized controlled trials and real-world studies have shown their utility in helping glycaemic management. In this review, we compare AID systems that are commercially available in the US and summarize the literature, with a special focus on time in range in T1DM. The review also discusses new AID systems on the horizon and explores considerations for personalized care.

Keywords: Automated insulin delivery; continuous glucose monitoring; dual hormone pump; glycemic management; hybrid closed loop system; time in range; type 1 diabetes mellitus.

PubMed Disclaimer

Conflict of interest statement

Disclosures: Armaan Nallicheri, Katherine M Mahoney and Hanna A Gutow have no financial or non-financial relationships or activities to declare in relation to this article. Natalie Bellini is a speaker for Abbott, and Diana Isaacs is a speaker for Abbott, Dexcom, and Medtronic and a consultant for Lifescan and Insulet.

References

    1. Heile M, Hollstegge B, Broxterman L. et al. Automated insulin delivery: Easy enough to use in primary care? Clin Diabetes. 2020;38:474–85. - PMC - PubMed
    1. Boughton CK, Hovorka R. Automated insulin delivery in adults. Endocrinol Metab Clin North Am. 2020;49:167–78. - PMC - PubMed
    1. Garg SK, Weinzimer SA, Tamborlane WV. et al. Glucose outcomes with the in-home use of a hybrid closed-loop insulin delivery system in adolescents and adults with type 1 diabetes. Diabetes Technol Ther. 2017;19:155–63. - PMC - PubMed
    1. Forlenza GP, Pinhas-Hamiel O, Liljenquist DR. et al. Safety evaluation of the MiniMed 670G system in children 7–13 years of age with type 1 diabetes. Diabetes Technol Ther. 2019;21:11–9. - PMC - PubMed
    1. Bergenstal RM, Garg S, Weinzimer SA. et al. Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. JAMA. 2016;316:1407–8. - PubMed

LinkOut - more resources